Czuczman, M S <br/><br/>
Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab.  [electronic resource] 

 -  Leukemia & lymphoma  Sep 2006 
 - 1830-40 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1042-8194 
<br/><br/><label>Standard No.: </label>10.1080/10428190600709523  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Agents--therapeutic use<br/>Biomarkers, Tumor--metabolism<br/>Disease Progression<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Lymphoma, B-Cell--drug therapy<br/>Lymphoma, Follicular--drug therapy<br/>Lymphoma, Non-Hodgkin--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Prospective Studies<br/>Rituximab<br/>Survival Rate<br/>Treatment Outcome